Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Darwin AG is a prominent player in the pharmaceutical and biotechnology sector, specializing in the development, manufacturing, and distribution of therapeutic medications and healthcare solutions. The company emphasizes innovation in drug development, focusing on creating effective treatments for various complex and rare diseases. With a robust pipeline of research initiatives, Darwin AG is dedicated to addressing unmet medical needs, leveraging advanced technology and scientific expertise. Operating globally, Darwin AG serves healthcare providers, clinics, and pharmaceutical companies, impacting sectors such as oncology, neurology, and immunology. The company's contributions to the pharmaceutical market underscore its commitment to improving patient outcomes and advancing healthcare solutions. Through strategic partnerships and collaborations with research institutions and healthcare organizations, Darwin AG plays a vital role in facilitating medical advancements and improving accessibility to necessary treatments. Its position in the market is critical, as it contributes to the development of breakthrough therapies and supports healthcare systems in improving global health standards.
€6.55
+€0.25 (+3.97%)
EOD Aug 7, 2026
The business is unprofitable at the operating level (-19.85% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 114.7%, still solid. Margins contracted 124.1pp, which offsets some of the top-line progress.
At 131x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 17.52% to -5.00%, capital efficiency is deteriorating.
131.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€54M
▲ +114.7% YoY
Net Income (TTM)
€545K
▼ -97.0% YoY
Op. Margin
-19.85%
▼ -124.1pp YoY
ROIC
-5.00%
▼ -22.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€22M
▲ +26.0% YoY
Op. Cash Flow (TTM)
€18M
▲ +13.8% YoY
Net Debt
-€47M
Net Cash Position
Cash & Equiv.
€53M
3Y CAGR: -36.3%
Continue Research
At a P/E of 131.0, A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Darwin scores 24/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 5.0%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Darwin scores 24 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -19.8% operating margin and a -5.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Darwin pays a regular dividend of about €0.33 per share per year (typically in quarterly installments), a yield of roughly 5.0% at the current price. That is a payout ratio of about 656.2% of earnings, so the dividend is stretched at this level. Darwin has grown the dividend at roughly 12.9% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 7V0.XETR's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh 7V0.XETR's valuation and scores 24/100 on quality (lower-quality). It also yields about 5.0%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.